familymednews.com
A research team at the University of Miami Miller School of Medicine’s Center for Therapeutic Innovation (CTI) has identified a novel epigenetic drug target to simultaneously normalize multiple deficits in Alzheimer’s disease (AD), the most common form of dementia in the elderly and the sixth leading cause of death in the U.S., according to the Alzheimer’s Association. The study, titled […]
Continue reading »
Problems like obesity and alcoholism appear to chronically trigger in the liver a receptor known to amplify inflammation in response to invaders like bacteria, scientists report. The relentless, increased activity of TREM-1 in turn accelerates injury and scarring of the liver, a first step toward cirrhosis and liver cancer, says Dr. Anatolij Horuzsko, reproductive immunologist in the Georgia Cancer Center […]
Continue reading »
University of Melbourne researchers have identified a protein involved in rheumatoid arthritis-induced inflammation that could lead to new drug treatments for people who do not respond to current therapies. Arthritis is Australia’s most common chronic disease and affects more than 3.5 million people. Rheumatoid arthritis (RA) affects about one per cent of the population and is one of the most […]
Continue reading »
Researchers at the University of Tsukuba and Kansai Medical University in Japan reveal matricellular protein Thrombospondin-1 (Thbs1) contributes to the development of aortic aneurysm in mice and humans. The thoracic aorta is constantly exposed to mechanical forces generated by heart contraction and blood flow. Thoracic aortic aneurysms (TAAs) are life-threatening diseases defined as a permanent abnormal dilatation of the thoracic […]
Continue reading »
Soap and mud are a natural fit. With that in mind, Walgreens Boots Alliance-owned Soap & Glory has signed on to be the first exclusive beauty sponsor of all Tough Mudder’s North American Challenge events. The partnership of the series of hardcore 10 to 12 obstacle races in the mud designed by British Special Forces kicks off this month with […]
Continue reading »
Medical researchers have identified a key signaling protein that regulates hemoglobin production in red blood cells, offering a possible target for a future innovative drug to treat sickle cell disease (SCD). Experiments in cultured human cells reveal that blocking the protein reduces the characteristic sickling that distorts the shape of red blood cells and gives the disease its name. “We […]
Continue reading »
Scientists from the University of Cambridge have identified a potential therapeutic target in the devastating genetic disease Hutchinson-Gilford Progeria Syndrome (HGPS), which is characterised by premature ageing. In a paper published today in Nature Communications, scientists provide preclinical data showing that chemical inhibition or genetic deregulation of the enzyme N-acetyltransferase 10 (NAT10) leads to significant health and lifespan gains in […]
Continue reading »
A team of Rutgers University and international scientists has determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC “urgent threat” bacterial pathogen Clostridium difficile (C. diff) and currently is one of two front-line drugs for treatment of C. diff. Fidaxomicin also exhibits potent antibacterial activity […]
Continue reading »